Search

New findings by researchers at MSK and their collaborators at the Icahn School of Medicine point to an opportunity to improve therapies that use small RNAs to silence disease-causing genes, potentially including those involved in cancer.

… Friday, December 20, 2024 In everyday life, when things turn out the opposite of what you expect, it’s usually cause for frustration. In science, it’s often the starting point for discovery. That’s what happened to a team of researchers from Memorial Sloan Kettering Cancer Center (MSK) and their collaborators

MSK investigators are leading research focused on understanding how hereditary DNA mutations affect cancer development and therapy, and how to best treat people who carry these inherited risks in their genes.

… Monday, June 5, 2023 Researchers from Memorial Sloan Kettering Cancer Center (MSK) revealed new findings about hereditary cancers and genetics at the recent 2023 American Society of Clinical Oncology (ASCO) annual meeting. Genetic mutations that are passed down through families cause a significant percentage

Patients with primary gastrointestinal stromal tumor, a type of tumor found in the stomach or small intestine, who received imatinib (Gleevec ®) after complete removal of their tumor were significantly less likely to have a recurrence of the cancer compared to those who did not receive imatinib.

… Thursday, April 12, 2007 Memorial Sloan Kettering Cancer Center’s Ronald DeMatteo, MD, served as the principal investigator of a large cooperative group trial that found patients with primary gastrointestinal stromal tumor, a type of tumor found in the stomach or small intestine, who received imatinib

For many patients, time is of the essence. At MSK, patients have access to potentially lifesaving therapies long before they are available at community hospitals. Learn how MSK’s Cancer Health Equity Research Program (CHERP) partners with a network of public hospitals in New York City to recruit underserved patients for clinical trials at MSK and give them access to world-class care.

… Tuesday, December 6, 2022 Berta Pesantez knew the outlook wasn’t good. She had stage 4 cancer of the bile duct , and the chemotherapy she was receiving at her local hospital wasn’t working. Out of options, the doctor transferred Berta to the New York’s Queens Cancer Center (QCC), in Jamaica. Berta’s

Select patients with papillary thyroid carcinoma with clinically involved lateral neck nodes may not require prophylactic central compartment neck dissection, enhancing quality of life.

… Monday, August 17, 2020 Select patients with papillary thyroid carcinoma with clinically involved lateral neck nodes (cN1b disease) may not require prophylactic central compartment neck dissection (PCND), according to our retrospective study published recently in the Annals of Surgical Oncology .  (1

Viviane Tabar, MD, has been named the new Chair of the Department of Neurosurgery at Memorial Sloan Kettering Cancer Center (MSK). Dr. Tabar has been a vital faculty member at MSK for more than 15 years and is currently the Theresa C. Feng Chair for Neurosurgical Oncology and the Vice Chair for Neurosurgical Research and Education.

… Wednesday, December 6, 2017 Viviane Tabar, MD , has been named the new Chair of the Department of Neurosurgery at Memorial Sloan Kettering Cancer Center (MSK). Dr. Tabar has been a vital faculty member at MSK for more than 15 years and is currently the Theresa C. Feng Chair for Neurosurgical Oncology

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

… Friday, October 15, 2021 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Luis Alberto Diaz, Jr. Appointed to the National Cancer Advisory Board by President Biden Luis Alberto Diaz, Jr. Luis Alberto Diaz, Jr., MD , Head of the Division of Solid Tumor Oncology

Memorial Sloan Kettering Cancer Center (MSK) today announced that Shelly Anderson, MPM, will join the institution as the inaugural Hospital President on September 25. Anderson joins MSK from Brigham and Women’s Hospital (BWH) in Boston, where she has been a member of the executive leadership team since 2011, most recently serving as Executive Vice President and Chief Operating Officer.

… Monday, June 26, 2023 Memorial Sloan Kettering Cancer Center (MSK) today announced that Shelly Anderson, MPM, will join the institution as the inaugural Hospital President on September 25. Anderson joins MSK from Brigham and Women’s Hospital (BWH) in Boston, where she has been a member of the executive

The event featured scientific talks from leading women in science, including winners of this year’s Kravis WISE fellowships.

… Friday, March 19, 2021 On March 17, 2021, scientists from around the world tuned in to watch the 2nd Annual Kravis WISE Symposium , a series of scientific talks sponsored by the Marie-Josée Kravis Women in Science Endeavor (WISE) at Memorial Sloan Kettering. Launched in 2020, Kravis WISE is devoted to

The Tri-Institutional Stem Cell Initiative, comprised of three leading New York City biomedical research institutions -- Memorial Sloan Kettering Cancer Center, The Rockefeller University, and Weill Medical College of Cornell University -- has announced the first wave of stem cell research projects to be funded through a $50 million gift from The Starr Foundation.

… Monday, July 31, 2006 First Research Projects to be Funded under the Tri-Institutional Stem Cell Initiative The Tri-Institutional Stem Cell Initiative , comprised of three leading New York City biomedical research institutions — Memorial Sloan Kettering Cancer Center, The Rockefeller University, and